UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 174

Sortiert nach

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

Cancer treatment reviews, 2020-04, Vol.85, p.101994-101994, Article 101994

2020

Volltextzugriff (PDF)

Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab

International journal of cancer, 2018-03, Vol.142 (6), p.1277-1284

2018

Volltextzugriff (PDF)

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis

Critical reviews in oncology/hematology, 2016-03, Vol.99, p.150-157

2016

Volltextzugriff (PDF)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer

Pharmaceuticals (Basel, Switzerland), 2020-12, Vol.13 (12), p.474

2020

Volltextzugriff (PDF)

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?

Frontiers in oncology, 2020-04, Vol.10, p.734-734

2020

Volltextzugriff (PDF)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

Oncotarget, 2016-09, Vol.7 (37), p.60712-60722

2016

Volltextzugriff (PDF)

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

Therapeutic advances in medical oncology, 2019, Vol.11, p.1758835919839928-1758835919839928

2019

Volltextzugriff (PDF)

Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials

PloS one, 2015-04, Vol.10 (4), p.e0124587-e0124587

2015

Volltextzugriff (PDF)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920942378-1758835920942378

2020

Volltextzugriff (PDF)

Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare

Frontiers in oncology, 2022-03, Vol.12, p.859903-859903

2022

Volltextzugriff (PDF)

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231151845-17588359231151845

2023

Volltextzugriff (PDF)

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Oncotarget, 2015-09, Vol.6 (28), p.24780-24796

2015

Volltextzugriff (PDF)

Network approach in liquidomics landscape

Journal of experimental & clinical cancer research, 2023-08, Vol.42 (1), p.193-193, Article 193

2023

Volltextzugriff (PDF)

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis

Therapeutic advances in medical oncology, 2019, Vol.11, p.1758835919874653-1758835919874653

2019

Volltextzugriff (PDF)

Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives

Cancers, 2024-06, Vol.16 (11), p.1967

2024

Volltextzugriff (PDF)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211018018-17588359211018018

2021

Volltextzugriff (PDF)

Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer

World journal of surgical oncology, 2021-10, Vol.19 (1), p.1-306, Article 306

2021

Volltextzugriff (PDF)

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement

Therapeutic advances in medical oncology, 2022-03, Vol.14, p.17588359221086829-17588359221086829

2022

Volltextzugriff (PDF)

The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors

Frontiers in endocrinology (Lausanne), 2023, Vol.14, p.1297950-1297950

2023

Volltextzugriff (PDF)

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

Frontiers in oncology, 2023-04, Vol.13, p.1141500-1141500

2023

Volltextzugriff (PDF)

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials

Critical reviews in oncology/hematology, 2019-10, Vol.142, p.68-75

2019

Volltextzugriff (PDF)

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Cancers, 2022-12, Vol.15 (1), p.216

2022

Volltextzugriff (PDF)

PROTACs: The Future of Leukemia Therapeutics

Frontiers in cell and developmental biology, 2022-09, Vol.10, p.851087-851087

2022

Volltextzugriff (PDF)

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(157)

Publikationsform

Sprache

Englisch
(174)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score

Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Network approach in liquidomics landscape

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis

Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses

Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement

The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials

Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

PROTACs: The Future of Leukemia Therapeutics

Suchergebnisse filtern